e-learning
resources
London 2016
Sunday, 04.09.2016
Best abstracts in exercise capacity and testing in chronic lung diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The reliability and validity of the 4 metre gait speed (4MGS) in idiopathic pulmonary fibrosis (IPF)
Claire M Nolan (London, United Kingdom), Claire M. Nolan, Matthew Maddocks, Jane L. Canavan, Sarah E. Jones, Samantha S.C. Kon, Athol U. Wells, David M. Hansell, Joseph Jacobs, Paul Cullinan, Toby M. Maher, William D.-C. Man
Source:
International Congress 2016 – Best abstracts in exercise capacity and testing in chronic lung diseases
Session:
Best abstracts in exercise capacity and testing in chronic lung diseases
Session type:
Poster Discussion
Number:
1572
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Claire M Nolan (London, United Kingdom), Claire M. Nolan, Matthew Maddocks, Jane L. Canavan, Sarah E. Jones, Samantha S.C. Kon, Athol U. Wells, David M. Hansell, Joseph Jacobs, Paul Cullinan, Toby M. Maher, William D.-C. Man. The reliability and validity of the 4 metre gait speed (4MGS) in idiopathic pulmonary fibrosis (IPF). Eur Respir J 2016; 48: Suppl. 60, 1572
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
ERS clinical practice guidelines on treatment of sarcoidosis
Related content which might interest you:
Clinical significance of falling oxygen saturation per walking distance (ΔSaO2/6MWD) during six minute walk test (6MWT) in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015
A six minute walking test (6MWT) derived index (O2-GAP) predicts mortality in IPF
Source: International Congress 2015 – IPF: clinical aspects II
Year: 2015
Test-retest reliability for the 30-meter walk test (30mWT) in patients with chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2010 - Exercise training: new groups, new methods and outcomes
Year: 2010
Idiopathic pulmonary fibrosis (IPF)
Source: ERS Course 2016
Year: 2016
Item generation for a patient reported outcome measure (PRoM) in idiopathic pulmonary fibrosis (IPF): Application of consensus methods
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015
Handigrip strenght and dynapenia in patients with idiopathic pulmonary fibrosis (IPF)
Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Year: 2020
The six minute walking test: Clinical predictors of survival in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –The latest insights in exercise testing and physical inactivity
Year: 2013
Effect of continued pirfenidone treatment following a ≥ 15% decline in 6-minute walk distance (6MWD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis from 3 pivotal studies
Source: International Congress 2016 – New and old therapies for chronic lung diseases
Year: 2016
Challenges in idiopathic pulmonary fibrosis trials: the point on end-points
Source: Eur Respir Rev 2011; 20: 195-200
Year: 2011
Sarcopenia in idiopathic pulmonary fibrosis (IPF): Prevalence and response to pulmonary rehabilitation (PR)
Source: Virtual Congress 2020 – Optimising the benefits of pulmonary rehabilitation
Year: 2020
All-case post-marketing surveillance (PMS) of pirfenidone in Japan: Clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Development of a patient reported experience measure (PREM) for idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis
Year: 2019
Effect of nintedanib on composite physiologic index (CPI) in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights
Year: 2017
Predictors of objective cough in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Year: 2019
Is there a relationship between quality of life and exercise performance in idiopathic pulmonary fibrosis (IPF)?
Source: Eur Respir J 2007; 30: Suppl. 51, 577s
Year: 2007
6-minute walk test (6MWT) in patients with idiopathic pulmonary fibrosis (IPF): Confirmation of the minimal clinically important difference (MCID)
Source: Annual Congress 2012 - Diffuse parenchymal lung disease III
Year: 2012
The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 25: 96-103
Year: 2005
Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases
Year: 2013
Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
The long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept